Tag: cardiac biomarkers testing market analysis

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Is The Cardiac Biomarkers Testing Market Expected To Grow In Terms Of Size?

There has been a significant expansion in the market size of cardiac biomarkers testing in the recent past. Projected growth indicates that it will rise from $13.48 billion in 2024, reaching a value of $14.95 billion in 2025 with a compound annual growth rate (CAGR) of 10.9%. The notable growth observed in the historic period is linked to factors such as a surge in cardiovascular disorders, an increase in the aging population, heightened awareness and education campaigns, government-led initiatives and healthcare strategies, and a rise in healthcare spending.

Over the coming years, the market size for cardiac biomarkers testing is anticipated to experience swift expansion. By 2029, it is projected to grow to a worth of “$23.24 billion, with a compound annual growth rate (CAGR) of 11.7%. Contributing factors to this projected growth include a rise in personalized medicine, an increasing worldwide prevalence of cardiovascular diseases, the use of artificial intelligence in diagnostics, widening of point-of-care testing, and escalating emphasis on detecting diseases at an early stage. Key trends to watch during this forecast period encompass technological innovations, developments in AI-facilitated diagnostics, expansion of point-of-care testing (POCT), enhanced multiplexing capabilities, and advancements in biomarker identification and validation.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

Which Demand Drivers Are Strengthening The Cardiac Biomarkers Testing Market?

The growth of the cardiac biomarkers testing market is anticipated to be propelled by the rising incidences of cardiovascular diseases. These diseases typically impact the heart or the blood vessels. Cardiac biomarker tests are crucial in identifying the levels of biomarkers for prompt assessment of the seriousness and scale of a heart attack. Consequently, a rise in cardiovascular diseases will result in higher demand for cardiac biomarker testing solutions. For example, projections from the American College of Cardiology, a professional medical entity based in the US, indicated in August 2022 that the rates of cardiovascular risk factors and disease are set to significantly increase in the United States by 2060. Hence, the increasing prevalence of cardiovascular diseases is spurring the growth of the cardiac biomarkers testing market.

What Is The Segment Breakdown Of The Cardiac Biomarkers Testing Market?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

How Are Global Trends Impacting The Development Of The Cardiac Biomarkers Testing Market?

Prominent companies in the cardiac biomarker testing market are forming strategic alliances to introduce technology for early detection of heart condition markers, thus improving patient prognosis. Such alliances in cardiac biomarker testing promote co-operation among businesses, paving way for innovative diagnostics, increasing market penetration, and speeding up the accessibility of advanced testing solutions for enhanced cardiac care. For instance, in September 2024, MediBuddy, an Indian healthcare tech firm offering an all-inclusive platform for telehealth services, health management, and insurance aid, formed an alliance with Philips, a conglomerate corporation based in Netherlands. The motive behind this partnership is to boost cardiac care in India by integrating Philips’ HeartPrint technology, enabling routine monitoring and evaluating risk factors of heart health. This progressive strategy equips users with superior tools on the MediBuddy platform, encouraging proactive management of cardiac health and improved outcomes.

Who Are The Leading Companies Driving The Cardiac Biomarkers Testing Market?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

Which Region Is Leading Innovation In The Cardiac Biomarkers Testing Market?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Cardiac Biomarkers Testing Market Through 2029?

In recent times, there has been significant growth in the market size for cardiac biomarkers testing. The market is projected to expand from $13.48 billion in 2024 to $14.95 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.9%. Factors contributing to the growth in the previous period include a rise in cardiovascular diseases, an aging population, initiatives concerning awareness and education, government schemes and health policies, and an upward trend in healthcare expenditure.

In the coming years, the cardiac biomarkers testing market is anticipated to experience swift expansion. The market is projected to escalate to “$23.24 billion in 2029, boasting a compound annual growth rate (CAGR) of 11.7%. Factors driving this incremental growth during the forecast period are the popularity of personalized medicine, the escalating worldwide prevalence of cardiovascular diseases, the incorporation of artificial intelligence in diagnostics, the broadening spectrum of point-of-care testing, and the increased focus on early detection of diseases. The forecast period also sees key trends such as technological progression, improvements in AI-supported diagnostics, the expansion of point-of-care testing (POCT), enhanced multiplexing capabilities, and the discovery and validation of biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

What Market Forces Are Driving The Cardiac Biomarkers Testing Sector In 2025 And Beyond?

The escalating occurrence of ailments related to the heart and blood vessels is predicted to propel the cardiac biomarkers testing market’s growth. Such diseases can significantly impact the heart and blood vessels, increasing the need for cardiac biomarker tests which can promptly discern the intensity and scale of a heart attack through biomarker levels. Consequently, increased heart-related diseases will boost the demand for these tests. For example, projections from the American College of Cardiology, a prominent U.S medical body in August 2022, suggest a striking rise in cardiovascular risk factors and disease in the country by 2060. Thus, the growing frequency of cardiovascular diseases is fuelling the expansion of the cardiac biomarkers testing market.

How Is The Global Cardiac Biomarkers Testing Market Categorized By Segments?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

How Are Key Trends Driving Expansion In The Cardiac Biomarkers Testing Industry?

Major players in the cardiac biomarker testing sector are leveraging strategic collaborations to offer technological solutions for early detection of heart diseases and enhancing patient outcomes. These strategic alliances are encouraging cooperation among companies, facilitating the creation of groundbreaking diagnostics, broadening their market presence, and hastening the access to technologically advanced testing solutions for enhanced cardiac care. For instance, MediBuddy, an Indian healthcare technology firm offering a wide-ranging platform for telehealth services, comprehensive health management, and insurance-related support, established a collaboration with Philips, a Dutch multinational conglomerate, in September 2024. The aim of this partnership is to fortify cardiac care within India by integrating Philips’ HeartPrint technology, therefore allowing regular checks and risk evaluation of cardiac health. This innovative way of approach endows users with advanced tools available on MediBuddy’s platform, thereby promoting proactive cardiac health management and improved outcomes.

Which Firms Are Considered Leaders In The Cardiac Biomarkers Testing Market Space?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

What Role Do Regional Policies And Investments Play In Cardiac Biomarkers Testing Market Expansion?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Cardiac Biomarkers Testing Market Through 2029?

In recent times, there has been significant growth in the market size for cardiac biomarkers testing. The market is projected to expand from $13.48 billion in 2024 to $14.95 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.9%. Factors contributing to the growth in the previous period include a rise in cardiovascular diseases, an aging population, initiatives concerning awareness and education, government schemes and health policies, and an upward trend in healthcare expenditure.

In the coming years, the cardiac biomarkers testing market is anticipated to experience swift expansion. The market is projected to escalate to “$23.24 billion in 2029, boasting a compound annual growth rate (CAGR) of 11.7%. Factors driving this incremental growth during the forecast period are the popularity of personalized medicine, the escalating worldwide prevalence of cardiovascular diseases, the incorporation of artificial intelligence in diagnostics, the broadening spectrum of point-of-care testing, and the increased focus on early detection of diseases. The forecast period also sees key trends such as technological progression, improvements in AI-supported diagnostics, the expansion of point-of-care testing (POCT), enhanced multiplexing capabilities, and the discovery and validation of biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

What Market Forces Are Driving The Cardiac Biomarkers Testing Sector In 2025 And Beyond?

The escalating occurrence of ailments related to the heart and blood vessels is predicted to propel the cardiac biomarkers testing market’s growth. Such diseases can significantly impact the heart and blood vessels, increasing the need for cardiac biomarker tests which can promptly discern the intensity and scale of a heart attack through biomarker levels. Consequently, increased heart-related diseases will boost the demand for these tests. For example, projections from the American College of Cardiology, a prominent U.S medical body in August 2022, suggest a striking rise in cardiovascular risk factors and disease in the country by 2060. Thus, the growing frequency of cardiovascular diseases is fuelling the expansion of the cardiac biomarkers testing market.

How Is The Global Cardiac Biomarkers Testing Market Categorized By Segments?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

How Are Key Trends Driving Expansion In The Cardiac Biomarkers Testing Industry?

Major players in the cardiac biomarker testing sector are leveraging strategic collaborations to offer technological solutions for early detection of heart diseases and enhancing patient outcomes. These strategic alliances are encouraging cooperation among companies, facilitating the creation of groundbreaking diagnostics, broadening their market presence, and hastening the access to technologically advanced testing solutions for enhanced cardiac care. For instance, MediBuddy, an Indian healthcare technology firm offering a wide-ranging platform for telehealth services, comprehensive health management, and insurance-related support, established a collaboration with Philips, a Dutch multinational conglomerate, in September 2024. The aim of this partnership is to fortify cardiac care within India by integrating Philips’ HeartPrint technology, therefore allowing regular checks and risk evaluation of cardiac health. This innovative way of approach endows users with advanced tools available on MediBuddy’s platform, thereby promoting proactive cardiac health management and improved outcomes.

Which Firms Are Considered Leaders In The Cardiac Biomarkers Testing Market Space?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

What Role Do Regional Policies And Investments Play In Cardiac Biomarkers Testing Market Expansion?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Cardiac Biomarkers Testing Market Through 2029?

In recent times, there has been significant growth in the market size for cardiac biomarkers testing. The market is projected to expand from $13.48 billion in 2024 to $14.95 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.9%. Factors contributing to the growth in the previous period include a rise in cardiovascular diseases, an aging population, initiatives concerning awareness and education, government schemes and health policies, and an upward trend in healthcare expenditure.

In the coming years, the cardiac biomarkers testing market is anticipated to experience swift expansion. The market is projected to escalate to “$23.24 billion in 2029, boasting a compound annual growth rate (CAGR) of 11.7%. Factors driving this incremental growth during the forecast period are the popularity of personalized medicine, the escalating worldwide prevalence of cardiovascular diseases, the incorporation of artificial intelligence in diagnostics, the broadening spectrum of point-of-care testing, and the increased focus on early detection of diseases. The forecast period also sees key trends such as technological progression, improvements in AI-supported diagnostics, the expansion of point-of-care testing (POCT), enhanced multiplexing capabilities, and the discovery and validation of biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

What Market Forces Are Driving The Cardiac Biomarkers Testing Sector In 2025 And Beyond?

The escalating occurrence of ailments related to the heart and blood vessels is predicted to propel the cardiac biomarkers testing market’s growth. Such diseases can significantly impact the heart and blood vessels, increasing the need for cardiac biomarker tests which can promptly discern the intensity and scale of a heart attack through biomarker levels. Consequently, increased heart-related diseases will boost the demand for these tests. For example, projections from the American College of Cardiology, a prominent U.S medical body in August 2022, suggest a striking rise in cardiovascular risk factors and disease in the country by 2060. Thus, the growing frequency of cardiovascular diseases is fuelling the expansion of the cardiac biomarkers testing market.

How Is The Global Cardiac Biomarkers Testing Market Categorized By Segments?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

How Are Key Trends Driving Expansion In The Cardiac Biomarkers Testing Industry?

Major players in the cardiac biomarker testing sector are leveraging strategic collaborations to offer technological solutions for early detection of heart diseases and enhancing patient outcomes. These strategic alliances are encouraging cooperation among companies, facilitating the creation of groundbreaking diagnostics, broadening their market presence, and hastening the access to technologically advanced testing solutions for enhanced cardiac care. For instance, MediBuddy, an Indian healthcare technology firm offering a wide-ranging platform for telehealth services, comprehensive health management, and insurance-related support, established a collaboration with Philips, a Dutch multinational conglomerate, in September 2024. The aim of this partnership is to fortify cardiac care within India by integrating Philips’ HeartPrint technology, therefore allowing regular checks and risk evaluation of cardiac health. This innovative way of approach endows users with advanced tools available on MediBuddy’s platform, thereby promoting proactive cardiac health management and improved outcomes.

Which Firms Are Considered Leaders In The Cardiac Biomarkers Testing Market Space?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

What Role Do Regional Policies And Investments Play In Cardiac Biomarkers Testing Market Expansion?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Cardiac Biomarkers Testing Market Through 2029?

Recent years have seen rapid expansion in the cardiac biomarkers testing market, with its size anticipated to rise from $13.48 billion in 2024 to $14.95 billion by 2025, marking an impressive compound annual growth rate (CAGR) of 10.9%. Growth observed in the historic period seems to be driven by a variety of factors including a rise in cardiovascular disease, an aging demographic, enhanced awareness and education efforts, government strategies and healthcare policies, as well as an uptick in healthcare spending.

In the coming years, a swift expansion is projected for the cardiac biomarkers testing market, with a size anticipated to reach $23.24 billion by 2029, propelled by a compound annual growth rate (CAGR) of 11.7%. Factors contributing to this advancement during the forecast timeframe include the implementation of personalized medicine, the escalating global prevalence of cardiovascular disorders, the assimilation of artificial intelligence (AI) within diagnostic procedures, the enlargement of point-of-care testing, and a growing emphasis on the early detection of illnesses. The market is also likely to see trends that include technological progressions, the development of AI-assisted diagnostics, an increase in point-of-care testing (POCT), advancements in multiplexing abilities, and progress in the discovery and validation of biomarkers.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

What Market Forces Are Driving The Cardiac Biomarkers Testing Sector In 2025 And Beyond?

The surge in occurrences of cardiovascular illnesses is anticipated to fuel the expansion of the cardiac biomarkers testing market in the future. Cardiovascular disease encompasses any condition impacting the heart or blood vessels. Testing for cardiac biomarkers aids in promptly assessing biomarker levels to determine the gravity of a heart attack and its extent. Consequently, a rise in cardiovascular disease cases increases the demand for cardiac biomarker testing solutions. For example, the American College of Cardiology, a professional medical organization based in the US, predicted in August 2022 that there would be a significant increase in cardiovascular risk factors and disease in the country by 2060. Hence, the rising incidence of cardiovascular diseases is propelling the growth of the cardiac biomarkers testing market.

How Is The Global Cardiac Biomarkers Testing Market Categorized By Segments?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

What Long-Term Trends Are Likely To Affect The Cardiac Biomarkers Testing Market?

Key players in the cardiac biomarker testing market are leveraging strategic alliances to offer technology that can detect early symptoms of heart problems and enhance patient recovery. These strategic collaborations in the realm of cardiac biomarker testing create a conducive environment for the companies to develop cutting-edge diagnostics, increase their market penetration, and expedite the provision of state-of-the-art testing solutions for superior cardiovascular management. For example, in September 2024, MediBuddy, a health tech firm based in India that provides a comprehensive program for telehealth services, health management, and assistance with insurance, entered into a partnership with Philips, a conglomerate incorporated in the Netherlands. The objective of this alliance is to improve cardiac health in India by integrating Philips’ HeartPrint technology, which allows for consistent monitoring and risk evaluation of cardiac health. Such progressive strategies equip the MediBuddy platform users with sophisticated tools, promoting active handling of heart health and yielding improved outcomes.

Which Firms Are Considered Leaders In The Cardiac Biomarkers Testing Market Space?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

What Role Do Regional Policies And Investments Play In Cardiac Biomarkers Testing Market Expansion?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cardiac Biomarkers Testing Market Grown from 2024 to 2025?

In recent times, the size of the cardiac biomarkers testing market has seen significant expansion. It is projected to surge from $13.48 billion in 2024 to $15.09 billion in 2025, with a compound annual growth rate (CAGR) of 12.0%. The accelerating growth during the historic period is linked to the rising occurrences of cardiovascular diseases, the aging demographic, educational and awareness programs, governmental regulations and healthcare policies, as well as the uptick in healthcare spending.

What Growth Rate Is Anticipated for the Cardiac Biomarkers Testing Market in the Coming Years?

The size of the cardiac biomarkers testing market is predicted to experience substantial growth in the coming years, and is anticipated to reach $23.75 billion in 2029 with a compound annual growth rate (CAGR) of 12.0%. Factors contributing to this growth during the prediction period include the advent of personalized medicine, a surge in global cardiovascular disease incidences, the utilization of artificial intelligence (AI) in diagnostics, the growth of point-of-care testing, and a growing focus on early disease detection. Key trends projected during this period involve technological advancements, progresses in AI-assisted diagnostics, the expansion of point-of-care testing (POCT), the ability to perform multiplexing, as well as progress in biomarker discovery and verification.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

Who Are the Leading Companies in the Cardiac Biomarkers Testing Market?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

What Are the Key Drivers of the Cardiac Biomarkers Testing Market?

The growth of the cardiac biomarkers testing market is projected to be fueled by the escalating occurrence of cardiovascular diseases. These diseases predominantly affect the heart or blood vessels. Cardiac biomarker tests are critical in measuring biomarker levels for immediate detection and assessment of a heart attack’s severity and scale. Consequently, the rising prevalence of cardiovascular diseases is expected to amplify the need for cardiac biomarker testing solutions. For example, in August 2022, the American College of Cardiology, a professional medical organization based in the US, forecasted a significant rise in incidence rates of cardiovascular risk factors and disease in the United States by 2060. Hence, the growing prevalence of cardiovascular diseases is propelling the cardiac biomarkers testing market expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smp

What Are the Key Market Segments in the Cardiac Biomarkers Testing Industry?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

What Are the Latest Trends in the Cardiac Biomarkers Testing Market?

In the cardiac biomarker testing market, leading enterprises are establishing strategic partnerships so to enable early detection of heart-related warning signs and enhance patient results. Cardiac biomarker testing collaborations foster synergy between companies, promoting the invention of cutting-edge diagnostics, broadening market penetration, and fast-tracking the supply of sophisticated testing solutions for enhanced cardiovascular treatment. For example, in September 2024, MediBuddy, a healthcare technology firm based in India that offers a comprehensive telehealth services, health management, and insurance assistance platform, formed alliance with Philips, a conglomerate corporation headquartered in the Netherlands. The aim of this collaboration is to elevate cardiac care in India through the integration of Philips’ HeartPrint technology, which allows regular tracking and risk evaluation of heart health. This progressive strategy equips users with state-of-the-art tools on the MediBuddy platform, encouraging proactive heart health management and improved outcomes.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

What Are the Key Regional Markets in the Cardiac Biomarkers Testing Industry?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9436

This Report Delivers Insight On:

1. How big is the cardiac biomarkers testing market, and how is it changing globally?

2. Who are the major companies in the cardiac biomarkers testing market, and how are they performing?

3. What are the key opportunities and risks in the cardiac biomarkers testing market right now?

4. Which products or customer segments are growing the most in the cardiac biomarkers testing market?

5. What factors are helping or slowing down the growth of the cardiac biomarkers testing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Cardiac Biomarkers Testing Market Grown from 2024 to 2025?

In recent times, the size of the cardiac biomarkers testing market has seen significant expansion. It is projected to surge from $13.48 billion in 2024 to $15.09 billion in 2025, with a compound annual growth rate (CAGR) of 12.0%. The accelerating growth during the historic period is linked to the rising occurrences of cardiovascular diseases, the aging demographic, educational and awareness programs, governmental regulations and healthcare policies, as well as the uptick in healthcare spending.

What Growth Rate Is Anticipated for the Cardiac Biomarkers Testing Market in the Coming Years?

The size of the cardiac biomarkers testing market is predicted to experience substantial growth in the coming years, and is anticipated to reach $23.75 billion in 2029 with a compound annual growth rate (CAGR) of 12.0%. Factors contributing to this growth during the prediction period include the advent of personalized medicine, a surge in global cardiovascular disease incidences, the utilization of artificial intelligence (AI) in diagnostics, the growth of point-of-care testing, and a growing focus on early disease detection. Key trends projected during this period involve technological advancements, progresses in AI-assisted diagnostics, the expansion of point-of-care testing (POCT), the ability to perform multiplexing, as well as progress in biomarker discovery and verification.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

Who Are the Leading Companies in the Cardiac Biomarkers Testing Market?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

What Are the Key Drivers of the Cardiac Biomarkers Testing Market?

The growth of the cardiac biomarkers testing market is projected to be fueled by the escalating occurrence of cardiovascular diseases. These diseases predominantly affect the heart or blood vessels. Cardiac biomarker tests are critical in measuring biomarker levels for immediate detection and assessment of a heart attack’s severity and scale. Consequently, the rising prevalence of cardiovascular diseases is expected to amplify the need for cardiac biomarker testing solutions. For example, in August 2022, the American College of Cardiology, a professional medical organization based in the US, forecasted a significant rise in incidence rates of cardiovascular risk factors and disease in the United States by 2060. Hence, the growing prevalence of cardiovascular diseases is propelling the cardiac biomarkers testing market expansion.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smp

What Are the Key Market Segments in the Cardiac Biomarkers Testing Industry?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

What Are the Latest Trends in the Cardiac Biomarkers Testing Market?

In the cardiac biomarker testing market, leading enterprises are establishing strategic partnerships so to enable early detection of heart-related warning signs and enhance patient results. Cardiac biomarker testing collaborations foster synergy between companies, promoting the invention of cutting-edge diagnostics, broadening market penetration, and fast-tracking the supply of sophisticated testing solutions for enhanced cardiovascular treatment. For example, in September 2024, MediBuddy, a healthcare technology firm based in India that offers a comprehensive telehealth services, health management, and insurance assistance platform, formed alliance with Philips, a conglomerate corporation headquartered in the Netherlands. The aim of this collaboration is to elevate cardiac care in India through the integration of Philips’ HeartPrint technology, which allows regular tracking and risk evaluation of heart health. This progressive strategy equips users with state-of-the-art tools on the MediBuddy platform, encouraging proactive heart health management and improved outcomes.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

What Are the Key Regional Markets in the Cardiac Biomarkers Testing Industry?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9436

This Report Delivers Insight On:

1. How big is the cardiac biomarkers testing market, and how is it changing globally?

2. Who are the major companies in the cardiac biomarkers testing market, and how are they performing?

3. What are the key opportunities and risks in the cardiac biomarkers testing market right now?

4. Which products or customer segments are growing the most in the cardiac biomarkers testing market?

5. What factors are helping or slowing down the growth of the cardiac biomarkers testing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cardiac biomarkers testing industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#What Are the Key Projections for the CAGR of the Cardiac Biomarkers Testing Market Size From 2025 to 2034?

The sector for cardiac biomarkers testing has experienced swift expansion in the past few years. The market is projected to surge from $13.48 billion in 2024 to $15.09 billion in 2025, showing a compound annual growth rate (CAGR) of 12.0%. The past growth can be credited to various factors such as the rising occurrence of heart-related diseases, a growing elderly population, increased awareness and educational programs, government actions and healthcare regulations, along with an upsurge in healthcare spending.

Expectations are high for a swift expansion of the cardiac biomarkers testing market in the coming years. The projections suggest that the market will reach a size of $23.75 billion by 2029, growing at a compound annual growth rate (CAGR) of 12.0%. The growth drivers for this period include the rise in personalized medicine, the increasing global impact of cardiovascular diseases, the incorporation of artificial intelligence in diagnostic procedures, the growth of point-of-care testing, and heightened focus on early disease detection. Key trends for the forecast window are expected to be technological innovations, progress in AI-aided diagnostics, point-of-care testing (POCT) expansion, multiplexing capabilities, and breakthroughs in biomarker discovery and validation.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Cardiac Biomarkers Testing Market?

The growth of the cardiac biomarkers testing market is projected to accelerate due to the rising occurrence of cardiovascular illnesses. These are conditions that have an impact on the heart or blood vessels. The purpose of cardiac biomarker tests is to immediately ascertain the severity and scale of a heart attack by gauging the levels of biomarkers. Thus, as the prevalence of cardiovascular diseases rises, so does the demand for cardiac biomarker testing solutions. For example, the American College of Cardiology, a US-based medical professional organization, predicted in August 2022 that the rates of cardiovascular disease and risk factors are expected to significantly increase in the United States by 2060. Consequently, the growing prevalence of cardiovascular diseases is fueling the expansion of the cardiac biomarkers testing market.

Which Primary Segments of the Cardiac Biomarkers Testing Market Are Driving Growth and Industry Transformations?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smp

Which Regions Are Key Players in the Growth of the Cardiac Biomarkers Testing Market?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Are the Most Significant Market Trends in the Cardiac Biomarkers Testing Market?

Prominent firms involved in the cardiac biomarker testing market are leveraging strategic collaborations to offer technology that aids in early detection of heart condition symptoms, thus enhancing patient results. These alliances encourage cooperation between corporations within the cardiac biomarker testing market, fostering the creation of novel diagnostic methods, expanding market accessibility, and hastening the availability of avant-garde solutions for superior cardiovascular care. For example, MediBuddy, an Indian health tech firm that provides a holistic platform for telemedicine, health management, and insurance support, collaborated with the Netherlands-based conglomerate, Philips, in September 2024. Through this alliance, they aspire to enrich cardiac healthcare in India using Philips’ HeartPrint technology, which allows for regular heart health monitoring and risk evaluation. This progressive strategy equips users of the MediBuddy platform with high-tech tools, promoting proactive heart health management and improved results.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

What Parameters Are Used to Define the Cardiac Biomarkers Testing Market?

Cardiac biomarkers testing refers to the tests to evaluate the quantities of cardiac biomarkers in blood. It is used to diagnose, assess, and keep track of people who may have acute coronary syndrome (ACS).

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9436

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Cardiac Biomarkers Testing Market?

The rise in cardiovascular diseases is anticipated to propel the growth of the cardiac biomarkers testing market. Cardiovascular diseases, essentially conditions impacting the heart or blood vessels, boost the need for cardiac biomarker tests, which help identify the levels of biomarkers and accurately gauge the severity and extent of a heart attack. Therefore, a surge in cardiovascular diseases will result in higher demand for cardiac biomarker testing solutions. For example, as per the American College of Cardiology, a US-based professional medical entity, there is a projected substantial increase in the rates of cardiovascular risk factors and diseases in the United States by 2060. Consequently, the growing prevalence of cardiovascular diseases is fuelling the expansion of the cardiac biomarkers testing market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

#What is the Anticipated CAGR of theCardiac Biomarkers Testing Market, and What Factors Will Drive It?

There has been a swift expansion in the size of the cardiac biomarkers testing market in the past few years. The market is projected to scale up from $13.48 billion in 2024 to $15.09 billion in 2025, showing a compound annual growth rate (CAGR) of 12.0%. Factors contributing to the growth during the historical period include rising cases of cardiovascular diseases, an aging population, knowledge and education drives, government plans and healthcare policies, and higher healthcare spending.

The market size for cardiac biomarkers testing is anticipated to experience substantial growth in the coming years, reaching a value of $23.75 billion in 2029 with a 12.0% compound annual growth rate (CAGR). This expected increase during the forecast period can be linked to various factors such as the emergence of personalized medicine, the escalating worldwide cardiovascular disease burden, the incorporation of artificial intelligence (AI) in diagnostics, proliferation of point-of-care testing and a heightened focus on early detection of diseases. Noticeable trends in this duration consist of progressive technological enhancements, improvements in AI-supported diagnostics, enlargement of point-of-care testing (POCT), burgeoning multiplexing capabilities, as well as biomarker identification and substantiation.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9436

What Are the Most Significant Market Trends Transforming theCardiac Biomarkers Testing Market?

Leading firms in the cardiac biomarker testing industry are forging strategic alliances for advancing technology for early detection of heart conditions, thus improving patient results. Such partnerships in the cardiac biomarker testing sphere promote inter-corporate cooperation, paving the way for ground-breaking diagnostics, widening market accessibility, and hastening the provision of advanced testing options for improved heart care. For example, in September 2024, MediBuddy, a health tech firm based in India that offers a wide-ranging platform for telemedicine services, health administration, and insurance support, formed a partnership with Philips, a conglomerate company based in the Netherlands. Through this alliance, the objective is to boost cardiac care in India by integrating Philips’ HeartPrint technology, enabling ongoing monitoring and risk evaluation for heart health. This proactive strategy equips users with advanced resources on the MediBuddy platform, fostering active heart health management and better results.

What Are the Top Market Players Propelling the Growth of theCardiac Biomarkers Testing Industry?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

Which Primary Segments of the Cardiac Biomarkers Testing Market Are Driving Growth and Industry Transformations?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=9436&type=smpGlobal Cardiac Biomarkers Testing Market, Global Cardiac Biomarkers Testing Market Report, Global Cardiac Biomarkers Testing Market Trends, Global Cardiac Biomarkers Testing Market Size

Browse Through More Reports Similar to the Gobal Cardiac Biomarkers Testing Maret 2025, By The Business Research Company:

Interventional Cardiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/interventional-cardiology-devices-and-equipment-global-market-report

Cardiovascular Monitoring And Diagnostic Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-monitoring-and-diagnostic-devices-and-equipment-global-market-report

Cardiovascular Medical Lasers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the cardiac biomarkers testing market?

In recent years, the cardiac biomarkers testing market has seen substantial growth. An increase from $13.48 billion in 2024 to an expected $15.09 billion in 2025, at a 12.0% compound annual growth rate (CAGR), is projected. The historic growth trajectory can be traced back to factors such as the rise in cardiovascular diseases, an aging demographic, awareness and education efforts, governmental actions and health policies, and escalated healthcare spending.

What will be the cardiac biomarkers testing market size in the future?

The market size for cardiac biomarkers testing is projected to experience substantial growth in the coming years, with its value expected to reach $23.75 billion in 2029, growing at a compound annual growth rate of 12.0%. This expected growth could be due to the advent of personalized medicine, an increasing global prevalence of cardiovascular diseases, the integration of artificial intelligence into diagnostics, the expansion of point-of-care testing, and a growing emphasis on early detection of diseases. Key trends expected during the forecast period include technological innovations, progress in AI-supported diagnostics, an expansion in point-of-care testing, enhanced multiplexing capabilities, and progress in biomarker discovery and validation.

Get your cardiac biomarkers testing market report here!

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-testing-global-market-report

What main drivers are fueling expansion in the cardiac biomarkers testing market?

The escalating occurrence of cardiovascular ailments is projected to propel the expansion of the cardiac biomarkers testing market in future. These diseases mainly impact the heart or blood vessels. The role of cardiac biomarker tests is to ascertain the concentration of biomarkers, which helps in promptly establishing the intensity and scale of a heart attack. Hence, an upswing in cardiovascular disease cases will result in a surge in demand for cardiac biomarker testing solutions. For example, the American College of Cardiology, a professional medical establishment based in the US, predicted in August 2022 that the rates of cardiovascular risk factors and disease could significantly escalate within the country by 2060. Consequently, the growing prevalence of cardiovascular diseases is catalyzing the growth of the cardiac biomarkers testing market.

What key areas define the segmentation of the global cardiac biomarkers testing market?

The cardiac biomarkers testing market covered in this report is segmented –

1) By Biomarkers Type: Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP And NT-proBNP), Ischemia Modified Albumin (IMA), Other Biomarkers Types

2) By Application: Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, Other Applications

3) By End-User: Hospitals, Specialty Clinics

Subsegments:

1) By Creatine Kinase (CK-MB): Total CK-MB, CK-MB Mass

2) By Troponins: Cardiac Troponin I (cTnI), Cardiac Troponin T (cTnT)

3) By Myoglobin: Total Myoglobin

4) By Natriuretic Peptides: B-Type Natriuretic Peptide (BNP), N-Terminal Pro B-Type Natriuretic Peptide (NT-ProBNP)

5) By Ischemia Modified Albumin (IMA): IMA Levels

6) By Other Biomarkers Types: C-Reactive Protein (CRP), Heart-Type Fatty Acid-Binding Protein (H-FABP), Soluble ST2

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9436&type=smp

Who are the dominant players expanding their reach in the cardiac biomarkers testing market?

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation

How are evolving market trends shaping cardiac biomarkers testing Strategies?

Prominent firms in the cardiac biomarker testing industry are forming strategic alliances to offer tech for detecting early symptoms of heart-related conditions and enhancing patient results. Collaborations via strategic alliances in cardiac biomarker testing boosts innovation in diagnostics, broadens market presence, and hastens the rollout of cutting-edge testing solutions, ensuring better cardiovascular care. For example, in September 2024, MediBuddy, an Indian health tech firm offering a broad platform for telehealth services, health administration, and insurance help, forged a partnership with Philips, a Dutch conglomerate. The goal of this partnership is to boost cardiac care in India by integrating Philips’ HeartPrint technology, which enables consistent monitoring and risk evaluation of heart health. This forward-looking strategy equips MediBuddy platform users with high-end tools, fostering preemptive management of heart health and ensuring better results.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9436

Which regions are emerging as leaders in the cardiac biomarkers testing market?

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Interventional Cardiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/interventional-cardiology-devices-and-equipment-global-market-report

Cardiovascular Monitoring And Diagnostic Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-monitoring-and-diagnostic-devices-and-equipment-global-market-report

Cardiovascular Medical Lasers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: